Justin Kao stands out among growth investors because he actually founded and ran Helix before joining DFJ Growth, and he's long believed health—not ancestry or curiosity—is the real large-scale use case for genetics, treating the genome more like a reusable platform than a one-time test. He also tends to favor scaled, system-level distribution over one-by-one consumer sign-ups, looks for data and analytics-driven approaches even in hands-on lab fields like diagnostics, and focuses on making genomics work at a population level rather than just being scientifically impressive.
About their Fund
DFJ Growth was founded in 2005 on the idea that strong tech companies would stay private longer and need a new kind of investor between venture capital and public markets, and it has grown independently from DFJ's earlier-stage arm, typically investing $10M–$25M in companies already growing over 100% a year with real product-market fit. The firm pairs capital with hands-on operating help from people who have scaled companies themselves, and it looks for founders solving big problems in areas like hardware, robotics, government and commercial dual-use, life tech, and consumer—not just enterprise software—often backing categories like electric vehicles, space, and crypto before they were widely popular, with early examples including Tesla, SpaceX, Coinbase, Unity, and Twitter.

















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































